Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Imaxio Signs an Option for a License Agreement with Merial

Published: Tuesday, December 18, 2012
Last Updated: Tuesday, December 18, 2012
Bookmark and Share
This option agreement confirms the potential of Imaxio’s antigen re-engineering technology to improve human and animal health vaccines.

Imaxio has announced the signing of an option for a license agreement with Merial, the animal health division of Sanofi.

The aim of this agreement is to develop an animal health vaccine based on Imaxio’s immune-enhancing IMX313 technology.

Merial will conduct an internal review of the IMX313 technology for a period of 12 to 18 months and depending on results, will sign a license agreement.

Details of the vaccine candidate and the financial terms of the agreement have not been disclosed.

The aim of IMX313, Imaxio’s proprietary technology for antigen re-engineering, is to significantly enhance the immune response and therefore, the efficacy of vaccines with which it is used.

In response to the challenge of certain inefficacious vaccine candidates, IMX313 is a high-potential solution, which would not only enable the dose to be reduced but also the number of revaccinations needed.

"This agreement with a world leader in the animal health sector such as Merial further confirms the significance of our IMX313 technology in developing more efficacious vaccines," said Alexandre Le Vert, managing director of Imaxio.

Vert continued, "We are committed to pursuing partnerships to license our immune-enhancing IMX313 technology for new indications. This will enable us to offer even more innovative solutions for key players in the animal health sector and on a larger scale, for vaccinations in general."

“Merial is a clear leader in the development and commercial registration of new vaccine technologies in animal health. We are very pleased to assess the progress of Imaxio’s IMX313 technology and this fits very well into the current strategic needs of Merial,” said Jean-Christophe Audonnet, senior director, research strategy and key alliances, Bio R&D Merial.

Audonnet continued, “This collaboration is an excellent example of the increase in opportunities created in the Lyonbiopole regional cluster.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Imaxio Signs an Option for a License Agreement with DKFZ
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus.
Friday, October 17, 2014
Imaxio Announces the First Human Clinical Trial Using its Pro-Immunogenic Technology IMX313, in Tuberculosis
IMX313 has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial.
Monday, September 16, 2013
Imaxio Announces the First Human Clinical Trial Using IMX313 in Tuberculosis
IMX313, Imaxio’s antigen re-engineering technology, has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial managed by the Jenner Institute at Oxford University.
Wednesday, September 04, 2013
Scientific News
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos